Relmada Therapeutics (NASDAQ:RLMD – Get Free Report) and Clearmind Medicine (NASDAQ:CMND – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability and dividends.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Relmada Therapeutics and Clearmind Medicine, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Relmada Therapeutics | 1 | 1 | 4 | 1 | 2.71 |
| Clearmind Medicine | 0 | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics currently has a consensus target price of $12.00, indicating a potential upside of 67.95%. Given Relmada Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Relmada Therapeutics is more favorable than Clearmind Medicine.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Relmada Therapeutics | N/A | N/A | -$57.38 million | ($1.09) | -6.56 |
| Clearmind Medicine | N/A | N/A | -$3.86 million | ($197.20) | -0.02 |
Relmada Therapeutics is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 96.1% of Clearmind Medicine shares are owned by institutional investors. 14.5% of Relmada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Relmada Therapeutics and Clearmind Medicine’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Relmada Therapeutics | N/A | -71.22% | -64.46% |
| Clearmind Medicine | N/A | -207.53% | -100.70% |
Risk and Volatility
Relmada Therapeutics has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500. Comparatively, Clearmind Medicine has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500.
Summary
Relmada Therapeutics beats Clearmind Medicine on 8 of the 12 factors compared between the two stocks.
About Relmada Therapeutics
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.
About Clearmind Medicine
Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.
Receive News & Ratings for Relmada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relmada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
